| ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients Y Razvi, S Chan, T McFarlane, E McKenzie, P Zaki, C DeAngelis, ... Supportive Care in Cancer 27, 87-95, 2019 | 159 | 2019 |
| The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis M Kuksis, Y Gao, W Tran, C Hoey, A Kiss, AS Komorowski, AJ Dhaliwal, ... Neuro-oncology 23 (6), 894-904, 2021 | 141 | 2021 |
| Ataxia–telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review KJ Jerzak, T Mancuso, A Eisen Current Oncology 25 (2), 176-180, 2018 | 107 | 2018 |
| Personalized breast cancer treatments using artificial intelligence in radiomics and pathomics WT Tran, K Jerzak, FI Lu, J Klein, S Tabbarah, A Lagree, T Wu, ... Journal of medical imaging and radiation sciences 50 (4), S32-S41, 2019 | 78 | 2019 |
| The incidence of bone metastasis after early-stage breast cancer in Canada A Liede, KJ Jerzak, RK Hernandez, SW Wade, P Sun, SA Narod Breast cancer research and treatment 156, 587-595, 2016 | 76 | 2016 |
| Endocrine therapy in endometrial cancer: an old dog with new tricks KJ Jerzak, L Duska, HJ MacKay Gynecologic oncology 153 (1), 175-183, 2019 | 63 | 2019 |
| Incidence of brain metastases in nonmetastatic and metastatic breast cancer: is there a role for screening? AS Komorowski, E Warner, HJ MacKay, A Sahgal, KI Pritchard, KJ Jerzak Clinical breast cancer 20 (1), e54-e64, 2020 | 56 | 2020 |
| Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications KJ Jerzak, J Cockburn, GR Pond, KI Pritchard, SA Narod, SK Dhesy-Thind, ... Breast cancer research and treatment 149, 293-301, 2015 | 48 | 2015 |
| VERONICA: randomized phase II study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4/6 inhibitors–efficacy, safety, and biomarker results GJ Lindeman, TM Fernando, R Bowen, KJ Jerzak, X Song, T Decker, ... Clinical Cancer Research 28 (15), 3256-3267, 2022 | 43 | 2022 |
| Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study S Habbous, K Forster, G Darling, K Jerzak, CMB Holloway, A Sahgal, ... Neuro-oncology advances 3 (1), vdaa178, 2021 | 38 | 2021 |
| Machine learning frameworks to predict neoadjuvant chemotherapy response in breast cancer using clinical and pathological features N Meti, K Saednia, A Lagree, S Tabbarah, M Mohebpour, A Kiss, FI Lu, ... JCO Clinical Cancer Informatics 5, 66-80, 2021 | 36 | 2021 |
| Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN)+ fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative … GJ Lindeman, R Bowen, KJ Jerzak, X Song, T Decker, FM Boyle, ... Journal of Clinical Oncology 39 (15_suppl), 1004-1004, 2021 | 35 | 2021 |
| A population-based analysis of breast cancer incidence and survival by subtype in Ontario women SJ Seung, AN Traore, B Pourmirza, KE Fathers, M Coombes, KJ Jerzak Current Oncology 27 (2), 191-198, 2020 | 34 | 2020 |
| Central nervous system-specific efficacy of CDK4/6 inhibitors in randomized controlled trials for metastatic breast cancer LV Nguyen, K Searle, KJ Jerzak Oncotarget 10 (59), 6317, 2019 | 32 | 2019 |
| Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: A 1-year longitudinal study EA Underwood, KJ Jerzak, G Lebovic, PA Rochon, C Elser, KI Pritchard, ... Supportive Care in Cancer 27, 3035-3043, 2019 | 31 | 2019 |
| Patients’ and oncologists’ knowledge and expectations regarding tumor multigene next-generation sequencing: A narrative review M Shirdarreh, O Aziza, RC Pezo, KJ Jerzak, E Warner The Oncologist 26 (8), e1359-e1371, 2021 | 28 | 2021 |
| Toronto workshop on late recurrence in estrogen receptor–positive breast cancer: part 1: late recurrence: current understanding, clinical considerations RJO Dowling, K Kalinsky, DF Hayes, FC Bidard, DW Cescon, ... JNCI Cancer Spectrum 3 (4), pkz050, 2019 | 20 | 2019 |
| Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study KJ Jerzak, JG Cockburn, SK Dhesy-Thind, GR Pond, KI Pritchard, ... Breast Cancer Research and Treatment 171, 709-717, 2018 | 19 | 2018 |
| Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer KJ Jerzak, S Deghan Manshadi, P Ng, M Maganti, JM McCuaig, M Bulter, ... Journal of Oncology Pharmacy Practice 24 (2), 83-90, 2018 | 19 | 2018 |
| Central nervous system–specific outcomes of phase 3 randomized clinical trials in patients with advanced breast cancer, lung cancer, and melanoma K Corbett, A Sharma, GR Pond, PK Brastianos, S Das, A Sahgal, ... JAMA oncology 7 (7), 1062-1064, 2021 | 16 | 2021 |
